

STANDARD MEDICARE PART B MANAGEMENT

TRETTEEN (coagulation Factor XIII A-subunit [recombinant])

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Tretten is indicated in patients with congenital factor XIII A-subunit deficiency for routine prophylaxis for bleeding.

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. CRITERIA FOR INITIAL APPROVAL

Congenital Factor XIII A-Subunit Deficiency

Authorization of 12 months may be granted for prophylactic treatment of congenital factor XIII A-subunit deficiency.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization for 12 months may be granted when all of the following criteria are met:

- A. The member is currently receiving therapy with Tretten.
- B. Tretten is being used to treat an indication enumerated in Section II.
- C. The member is receiving benefit from therapy (e.g., reduced frequency or severity of bleeds).

IV. SUMMARY OF EVIDENCE

The contents of this policy were created after examining the following resources:

1. The prescribing information for Tretten.
2. The available compendium
 - a. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
 - b. Micromedex DrugDex

Reference number(s)
5002-A

- c. American Hospital Formulary Service- Drug Information (AHFS-DI)
 - d. Lexi-Drugs
 - e. Clinical Pharmacology
3. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders.

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Tretten are covered.

V. EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

VI. REFERENCES

1. Tretten [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; June 2020.
2. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised March 2022. MASAC Document #272. https://www.hemophilia.org/sites/default/files/document/files/272_Treatment.pdf. Accessed October 4, 2022.